PExA Signs 7.5 MSEK Contract with Top-10 Global Pharma for IPF Clinical Study Using PEXA 2.1 Systems
核心洞察
PExA (搜索) signed an 18-month, 7.5 MSEK contract with a top-10 global pharmaceutical company for 10 PEXA 2.1 (搜索) systems to support an international idiopathic pulmonary fibrosis (搜索) (IPF) clinical study.
The commercial milestone was accompanied by a strengthened financial position, with over 26 MSEK raised post-period through oversubscribed rights and directed share issues.
H1 2026 net loss improved to -2,199,311 SEK from -4,563,974 SEK year-over-year, while H1 revenue rose to 1,188,559 SEK from 312,581 SEK.
PExA (搜索) has secured a major commercial milestone, signing an 18-month, 7.5 MSEK contract with a top-10 global pharmaceutical company for the delivery of 10 PEXA 2.1 (搜索) systems to support an international idiopathic pulmonary fibrosis (搜索) (IPF) clinical study. The agreement, reported in the company's Q2 2026 earnings summary, marks a significant validation of the PEXA 2.1 platform for respiratory disease research.
Commercial Milestone and Clinical Application
The contract calls for 10 PEXA 2.1 (搜索) systems to be deployed in an international IPF clinical study over an 18-month period. The PEXA 2.1 system is designed to enable non-invasive sampling of the small airway lining fluid, a capability that supports biomarker analysis in respiratory disease research. The identity of the top-10 global pharma partner was not disclosed in the source materials.
Financial Performance
PExA (搜索) reported revenue of 82,800 SEK for Q2 2026, down from 312,582 SEK in Q2 2025. On a half-year basis, H1 2026 revenue reached 1,188,559 SEK, a substantial increase from 312,581 SEK in H1 2025.
Net loss after financial items improved to -1,246,669 SEK in Q2 2026, compared with -2,315,399 SEK in Q2 2025. For the first half of 2026, net loss was -2,199,311 SEK, an improvement from -4,563,974 SEK in the prior-year period.
Cash and cash equivalents at June 30, 2026, stood at 796,326 SEK, down from 1,683,318 SEK at June 30, 2025. The equity ratio at period end was 53.0%, compared with 67.1% a year earlier. Cash flow from operations in Q2 2026 was -1,924,402 SEK, with total cash flow of -3,021,396 SEK for the quarter.
Strengthened Financial Position
Following the period, PExA (搜索) strengthened its financial position by raising over 26 MSEK through oversubscribed rights and directed share issues. This capital raise, combined with the new commercial contract, positions the company to support its ongoing operations and the deployment of PEXA 2.1 (搜索) systems for the IPF study.